The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics : A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of the American Academy of Dermatology - 83(2020), 5 vom: 01. Nov., Seite 1523-1526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Syed, Maha N [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.10.2020 Date Revised 09.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jaad.2020.06.1014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312006004 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312006004 | ||
| 003 | DE-627 | ||
| 005 | 20231225143457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaad.2020.06.1014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM312006004 | ||
| 035 | |a (NLM)32622891 | ||
| 035 | |a (PII)S0190-9622(20)32115-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Syed, Maha N |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics |b A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2020 | ||
| 500 | |a Date Revised 09.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a IL23A protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-23 Subunit p19 |2 NLM | |
| 650 | 7 | |a guselkumab |2 NLM | |
| 650 | 7 | |a 089658A12D |2 NLM | |
| 650 | 7 | |a risankizumab |2 NLM | |
| 650 | 7 | |a 90ZX3Q3FR7 |2 NLM | |
| 650 | 7 | |a tildrakizumab |2 NLM | |
| 650 | 7 | |a DEW6X41BEK |2 NLM | |
| 700 | 1 | |a Shin, Daniel B |e verfasserin |4 aut | |
| 700 | 1 | |a Wan, Marilyn T |e verfasserin |4 aut | |
| 700 | 1 | |a Winthrop, Kevin L |e verfasserin |4 aut | |
| 700 | 1 | |a Gelfand, Joel M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American Academy of Dermatology |d 1984 |g 83(2020), 5 vom: 01. Nov., Seite 1523-1526 |w (DE-627)NLM000422703 |x 1097-6787 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2020 |g number:5 |g day:01 |g month:11 |g pages:1523-1526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaad.2020.06.1014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2020 |e 5 |b 01 |c 11 |h 1523-1526 | ||